Haleon plc

Informe acción NYSE:HLN

Capitalización de mercado: US$41.1b

Haleon Dirección

Dirección controles de criterios 4/4

El CEO de Haleon es Brian McNamara , nombrado en Jul 2021, tiene una permanencia de 4.83 años. compensación anual total es £8.23M, compuesta por 16.3% salario y 83.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.034% de las acciones de la empresa, por valor de $14.13M. La antigüedad media del equipo directivo y de la junta directiva es de 2.3 años y 3.8 años, respectivamente.

Información clave

Brian McNamara

Chief Executive Officer (CEO)

UK£8.2m

Compensación total

Porcentaje del salario del CEO16.29%
Permanencia del CEO4.8yrs
Participación del CEO0.03%
Permanencia media de la dirección2.3yrs
Promedio de permanencia en la Junta Directiva3.8yrs

Actualizaciones recientes de la dirección

Recent updates

Seeking Alpha • Feb 27

Haleon: Decent Earnings Growth Is Already Reflected In Valuation

Summary Haleon remains a solid, premium-branded consumer health company, but I maintain a 'hold' rating due to limited growth drivers and full valuation. Organic revenue grew 3%, below medium-term targets, with North America showing a modest decline and ongoing consumer confidence risks. Profitability improved, with operating profit up 9% and EPS up 18%, driven by productivity and disciplined investment, but future brand equity and marketing spend warrant monitoring. The dividend is set to grow 7.6%, and buybacks continue, yet cash flow communication is unclear, and the current 21x earnings multiple limits upside. Read the full article on Seeking Alpha
Seeking Alpha • Mar 05

Haleon: Growing Profits And Dividend

Summary I initiate coverage on Haleon with a "hold" rating due to decent results and potential for ongoing growth, despite a slight revenue slip last year. Haleon's dividend grew 10% and is well-covered by free cash flow, but the 1.6% yield is less attractive compared to peers. The balance sheet is manageable with net debt at 22% of market cap, though I question the optimality of share buybacks at current prices. The current valuation, with a P/E ratio of 26, isn't compelling for new investment, though ongoing earnings growth suggests no reason for existing shareholders to sell. Read the full article on Seeking Alpha
Seeking Alpha • Dec 10

Haleon: Guidance Implies Uncertainty Around Flu Season

Summary Haleon plc is logging solid organic performances led by their solid brand portfolio for oral health with brands like Sensodyne and Parodontax. This is despite some tough comps still in the results, particularly in VMS. Guidance remains around the 4-6% organic growth figure, ignoring FX effects, despite the momentum in the Q3. This reflects that there is still uncertainty of how much of a plus this year's flu season will be for respiratory products, despite the weak comp. The biggest observation we make though is that the HLN stock valuation is just not attractive enough. Read the full article on Seeking Alpha
Seeking Alpha • Oct 24

Haleon: Tailwinds Are Mostly Priced In

Summary Haleon's share price increased by 20% since July, mainly driven by strong H1 2024 results and strategic moves, among them, increasing their stake in Tianjin TSKF Pharmaceutical. The upcoming launch of Eroxon and China's stimulus pack could improve future sales, but debt maturity in 2025 may hinder deleveraging plans. Institutional investor activity shows growing optimism in Q2 2024, but recent major fund buying is absent, contributing to the mixed outlook. Despite strong cash flow and organic growth in most of its key brands, high leverage and mixed valuation ratios lead to a Hold rating for Haleon. Read the full article on Seeking Alpha
Seeking Alpha • Aug 06

Haleon: Defensive Consumer Healthcare Stock As Safe Haven

Summary Haleon is a consumer healthcare company formed from a GSK and Pfizer merger, with a 50% share price increase since trading began. Financial results show strong cash flows, with a net profit of 754M GBP and EPS of 7.90 pence per share in the first half of the year. Investment thesis suggests writing put options due to the high EBITDA multiple, with the potential for decreasing net debt and increasing EBITDA in the future. Read the full article on Seeking Alpha
Seeking Alpha • Nov 20

The Investment Case For Haleon: Steady Shareholder Value Accumulation

Summary Haleon plc is a promising company in the personal care products sector, with a low beta and cheap valuation. The company operates globally and has leading brands in oral health, painkillers, and vitamins. Haleon's ownership structure is interconnected with Pfizer and GSK, but divestitures could increase competitive pressures. My valuation analysis suggests the stock is significantly undervalued, implying a 44.6% upside potential and an $11.92 price target. Read the full article on Seeking Alpha
Seeking Alpha • Sep 07

The Share Price Has The Flu, But Haleon Is As Healthy As An Ox

Summary Haleon's share price has slumped, but its performance is relatively better compared to its consumer staples peers and the recent listing Kenvue. HLN has delivered solid results with organic revenue growth, increased operating profits, and raised revenue forecasts for FY2023. The company is optimizing its portfolio, divesting the Lamisil brand, reducing debt, and generating strong cash flow. Power brands are driving performance. Read the full article on Seeking Alpha
Seeking Alpha • Jun 12

Haleon: A Hidden Gem In The Consumer Health Market

Summary Haleon has a strong portfolio of leading brands and is well-positioned to benefit from ongoing market expansions. The company's latest earnings were strong, with double-digit growth in both the top and the bottom line. Despite the solid fundamentals and growth, its current valuation remains discounted compared to peers. I rate the company as a buy. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Haleon exploring sale of ChapStick Brand - report

Haleon Plc (NYSE:HLN), the consumer health unit spun off from GSK Plc last year, is evaluating a sale of its ChapStick lip balm brand. The company is working with advisers and the business could see $600 million in a potential sale, according to a Bloomberg report from Friday, which cited people familiar. Deliberations on a possible sale are said to be at an early stage. The news comes after Bloomberg late last month reported that Haleon (HLN) was in the early stages of evaluating large potential deals to increase the size of its brand portfolio. Haleon was said to be studying possible deals in the medium-to-long-term, including potentially combining with Sanofi's (SNY) $30 billion consumer-health business. Haleon (HLN) is set to report Q4 results on Thursday. Also see SA contributor Yannick Frey's piece from last month entitled "Haleon: A Great Consumer Staples Add."
Seeking Alpha • Jan 31

Haleon said to evaluate potential deals to increase its size - report

Haleon Plc (NYSE:HLN), the consumer health business spun of from pharmaceutical giant GSK Plc (GSK), is in the early stages of evaluating large potential deal to increase the size of its brand portfolio. Haleon (HLN) is studying possible deals in medium-to-long-term, including potentially combining with Sanofi's (NASDAQ:SNY) $30 billion consumer-health business, according to traders, who cited a Bloomberg report. The maker of Advil pain reliever and Aquafresh toothpaste is expected to wait until it can show several quarters of profit grown and debt paydown before it goes forward with any big transactions, according to the report. The report comes as Johnson & Johnson (JNJ) is preparing to list its consumer health business this year, though analysts cautioned on Monday that the legal judgement against J&J in talc litigation may complicate that process. Bayer (OTCPK:BAYRY) is also seeing pressure from activists investors, including one who earlier this month pushed for the German company to separate its crop sciences business from its consumer drug business.
Seeking Alpha • Aug 31

Haleon: Undervalued With Clear Catalyst Ahead

Summary Haleon has tumbled 20% since trading began in July. The stock is undervalued relative to its peers. The announcement of a dividend should boost the stock to higher levels. Earlier this year, GSK plc (GSK) decided to focus its business on vaccines and prescription medication. As a result, the company spun-off its consumer health business. The newly created company, Haleon plc (HLN), is now the largest standalone consumer health business. It owns many household brands, including Advil, Emergen-C, Tums and Sensodyne. The company is a powerhouse in the consumer staples industry, with around $11.5 billion in annual sales. The stock began trading on July 18, 2022, and has been steadily trading lower, down 20% since trading started. This article will focus on the stock's value versus peers as well as a significant catalyst that could lead to the stock finding a floor and climbing higher. Haleon Fact Sheet Haleon is Undervalued Yahoo Finance and CNBC Anyway, you analyze Haleon, it is undervalued versus its peers in the industry. Comparing Haleon to three of the biggest companies in consumer staples - Procter & Gamble (PG), Unilever (UL, UNLYF), and Kimberly-Clark (KMB) - the company stacks up well on a number of valuation metrics. Its P/E value of 14.6 is 56% below the average P/E ratio of the 3 peers. This also puts the stock at a discount to the broader S&P 500 as well. Whenever you see a stock trading at a steep discount to its peers, investors should then look at the company's margin and growth level to see if the undervaluation is warranted. Here, you can again see Haleon stacking up very well. The company has an attractive net margin of 15.7%, which is well above Unilever and Kimberly-Clark. Perhaps, more importantly, the company expects its margins to hold up even in today's challenging market environment. Haleon saw a very strong second quarter revenue growth of 12.9% and organic revenue growth of 7.5%. The organic revenue growth came from a 4% increase in price and improved volumes of 3.5%. This combination shows consumers are willing to pay higher prices to continue to buy Haleon's product lineup in a very competitive market. For the full year FY2022, the company expects organic growth of 6-8% and 4-6% over the following 2 years. This steady growth is exactly what investors want to see and is attractive versus its peers over a 5-year period. PG Revenue (Annual YoY Growth) data by YCharts Haleon Underperformance With Haleon having attractive revenue growth, healthy margins and trading at a discount relative to its peers, why has the stock performed so poorly since its debut? Both the company and the stock are in a transition period. When Haleon was spun-off from GSK, all GSK shareholders received 1 Haleon share for every GSK share they held. 54.5% of Haleon stock was held by GSK shareholders at the time of the spin-off. These investors held GSK for exposure to pharma and not necessarily consumer healthcare. As a result, many of the current GSK shareholders likely sold during the first few weeks as it didn't meet their portfolio needs or sold to raise cash in a very uncertain market. In addition, shortly after it began trading as a standalone company, news of a growing lawsuit emerged that targeted a probable carcinogen in the popular heartburn drug, Zantac. Zantac was originally formulated and sold by GSK in the 1980s. GSK's patent expired in 1997, and since then numerous pharmaceutical companies have owned the rights to Zantac, including Pfizer (PFE), Sanofi (SNY) and Boehringer Ingelheim. With the first legal proceedings of this lawsuit starting in late August, investors began to fear an outcome similar to that faced by Bayer when they agreed to a $10.9 billion settlement related to lawsuits targeting a link between Roundup and cancer. However, the lawsuit targeting Zantac is extremely complex due to the drug being sold for nearly 4 decades by numerous different pharma companies. These lawsuits will be locked up in the courts for years to come and has a long way to go before any outcome is even clear. Haleon shares fell over 10% as news of the start of the trial emerged. Haleon issued a statement about the lawsuit where they stated Haleon is not a party to any of the Zantac claims and the company never marketed Zantac in any form in the U.S. Haleon may end up having some exposure to the lawsuit, but it will likely be limited due to the number of other companies involved, and no clear result will be known for years. As a result, the issue should remain on investors' radar, but shouldn't be front of mind or alter investment decisions. Haleon Catalyst As I said above, Haleon's stock is in a transition period and in a bit of a no-man's land. It's a newly created consumer healthcare company with plenty of comps, but the biggest difference between it and its peers is the dividend. Currently, Haleon pays no dividend. As a result, it doesn't meet many investor needs or criteria. Mutual funds, pensions, endowments and retail investors are large holders of Procter & Gamble, Unilever and Kimberly-Clark because they are steady businesses during favorable and unfavorable economic conditions that pay a steady dividend. Currently, Haleon doesn't offer this steady income that many investors rely on in their portfolios. However, the company has stated they intend to start paying a dividend at the lower end of a 30-50% payout ratio. Assuming the company starts its payout ratio at 30% and EPS of 0.42, the initial dividend will likely be around $0.12-$0.13/share. This would give the stock an initial dividend yield around 2% based on its current price around $6/share. This would also give the company plenty of room to accomplish their other objective to get their net debt/EBITDA under 3 by the end of 2024.
Seeking Alpha • Aug 19

Former GSK consumer health unit Haleon hits all-time low

Haleon (NYSE:HLN), which only began trading on the NYSE on July 19, has fallen to an all-time low. The GlaxoSmithKline (GSK) consumer healthcare spinoff opened that date at $7.25. Earlier Friday, it reached a low of $5.95. Haleon (HLN) and GSK (GSK) have both been negatively impacted recently by potential exposure to litigation related to the recalled heartburn drug Zantac (ranitidine).
Seeking Alpha • Jul 20

Haleon CEO says brand recognition, gross margins will drive growth - CNBC

On its third day as a company separate from GlaxoSmithKline (GSK), Haleon (HLN) CEO Brian McNamara said that the customer recognition of its many brands combined with hits high gross margin rate will power growth in the future, he said. In an interview on CNBC's "Squawk Box" Wednesday morning, McNamara said that the former GSK (GSK) consumer healthcare unit had a gross margin of 63% and an operating margin of 22.8% in 2021. "With that gross margin and strength in brands, [it] really gives us the ability to invest in innovation and advertising and promotion to really drive the fundamental growth of the business," he added. Despite a plethora of store and generic-branded consumer healthcare products, McNamara noted that "brands really matter in the health space." Haleon (HLN) management has previously guided to 4%-6% net sales growth annually. Haleon (HLN) began trading on the London Stock Exchange on Monday. Since then, shares are down ~8%. The company made its trading debut on the NYSE today. In late morning trading, shares are up 0.4%.

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Brian McNamara en comparación con los beneficios de Haleon?
FechaCompensación totalSalarioIngresos de la empresa
Dec 31 2025UK£8mUK£1m

UK£2b

Sep 30 2025n/an/a

UK£1b

Jun 30 2025n/an/a

UK£2b

Mar 31 2025n/an/a

UK£1b

Dec 31 2024UK£9mUK£1m

UK£1b

Sep 30 2024n/an/a

UK£1b

Jun 30 2024n/an/a

UK£1b

Mar 31 2024n/an/a

UK£1b

Dec 31 2023UK£6mUK£1m

UK£1b

Sep 30 2023n/an/a

UK£1b

Jun 30 2023n/an/a

UK£1b

Mar 31 2023n/an/a

UK£1b

Dec 31 2022UK£2mUK£719k

UK£1b

Compensación vs. Mercado: La compensación total ($USD11.12M) de Brian está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD14.79M).

Compensación vs. Ingresos: La compensación de Brian ha sido consistente con los resultados de la empresa en el último año.

CEO

Brian McNamara (59 yo)

4.8yrs
Permanencia
UK£8,230,000
Compensación

Mr. Brian James McNamara serves as Independent Director at Mondelez International, Inc. since February 01, 2024. He serves as Chief Executive Officer at Haleon plc and serves as its Executive Director sinc...

Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Brian McNamara
CEO & Executive Director4.8yrsUK£8.23m0.034%
$ 14.1m
Dawn Allen
CFO & Director1.5yrsUK£3.06m0.0021%
$ 847.6k
Claire Dickson
Chief Digital & Technology Officer1.7yrssin datossin datos
Joanne Russell
Head of Investor Relationsno datasin datossin datos
Adrian Morris
General Counsel1.8yrssin datossin datos
Tamara Rogers
Chief Marketing Officer4.4yrssin datos0.0033%
$ 1.3m
Line De Decker
Chief Human Resources Officer1.8yrssin datossin datos
Filippo Lanzi
President of EMEA & LatAmno datasin datos0.0040%
$ 1.7m
Keith Choy
President of Asia Pacificno datasin datos0.0064%
$ 2.6m
Bjorn Timelin
Head of Strategy2.6yrssin datossin datos
Namrata Patel
Chief Supply Chain Officer2.5yrssin datossin datos
Ed Petter
Chief Corporate Affairs Officer2.3yrssin datossin datos
2.3yrs
Permanencia media
57yo
Promedio de edad

Equipo directivo experimentado: El equipo directivo de HLN se considera experimentado (2.3 años antigüedad media).

Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Brian McNamara
CEO & Executive Director4yrsUK£8.23m0.034%
$ 14.1m
Dawn Allen
CFO & Director1.5yrsUK£3.06m0.0021%
$ 847.6k
Dame Cox
Independent Non-Executive Director3.8yrsUK£133.60ksin datos
Manvinder Banga
Independent Non-Executive Chair3.8yrsUK£152.70k0.0037%
$ 1.5m
Matthew John Shattock
Independent Non-Executive Directorless than a yearUK£61.00ksin datos
Tracy Clarke
Independent Non-Executive Director3.8yrsUK£143.60k0.00014%
$ 57.6k
Alan James Stewart
Senior Independent Director1.7yrsUK£143.20k0.00040%
$ 164.6k
Blathnaid Bergin
Independent Non-Executive Director1.3yrsUK£87.40k0.000070%
$ 28.8k
Nancy Avila
Independent Non-Executive Director1.7yrsUK£105.00ksin datos
Marie-Anne Aymerich
Independent Non-Executive Director3.8yrsUK£140.50k0.00056%
$ 230.4k
Asmita Dubey
Independent Non-Executive Director3.8yrsUK£103.00k0.00017%
$ 69.9k
3.8yrs
Permanencia media
59yo
Promedio de edad

Junta con experiencia: La junta directiva de HLN se considera experimentada (3.8 años de antigüedad promedio).

Análisis de la empresa y estado de los datos financieros

DatosÚltima actualización (huso horario UTC)
Análisis de la empresa2026/05/26 19:01
Precio de las acciones al final del día2026/05/22 00:00
Beneficios2025/12/31
Ingresos anuales2025/12/31

Fuentes de datos

Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.

PaqueteDatosMarco temporalEjemplo Fuente EE.UU. *
Finanzas de la empresa10 años
  • Cuenta de resultados
  • Estado de tesorería
  • Balance
Estimaciones del consenso de analistas+3 años
  • Previsiones financieras
  • Objetivos de precios de los analistas
Precios de mercado30 años
  • Precios de las acciones
  • Dividendos, escisiones y acciones
Propiedad10 años
  • Accionistas principales
  • Información privilegiada
Gestión10 años
  • Equipo directivo
  • Consejo de Administración
Principales avances10 años
  • Anuncios de empresas

* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.

A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.

Modelo de análisis y copo de nieve

Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.

Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.

Métricas industriales y sectoriales

Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.

Fuentes analistas

Haleon plc está cubierta por 28 analistas. 16 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.

AnalistaInstitución
Iain SimpsonBarclays
Warren AckermanBarclays
Bethan DaviesBerenberg